stockportfolio.pro
Biogen Inc. (BIIB)
Healthcare · Drug Manufacturers - General · NasdaqGS
Biogen Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.45B | $12.27B | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.89B |
| Gross profit | $9.97B | $10.64B | $11.64B | $12.42B | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| Net income | $3.70B | $2.54B | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Net margin | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
Source: Biogen Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into BIIB stock?
At today's market cap of $29.39B, Biogen Inc. is priced for free-cash-flow growth of about 3.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.05B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -11.6%/yr over the last five fiscal years and revenue -6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Biogen Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BIIB in your portfolio →
Biogen Inc. financial history by metric
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc. — frequently asked questions
What is Biogen Inc.'s revenue?
Biogen Inc. (BIIB) reported revenue of $9.89B for fiscal year 2025, up 2.2% from the prior year, according to its SEC filings.
Is Biogen Inc. profitable?
Yes. BIIB earned net income of $1.29B in fiscal 2025, a net margin of 13.1%.
What is BIIB's P/E ratio?
Biogen Inc. trades at a price-to-earnings ratio of about 21.4 based on the latest data in our nightly-refreshed cache.
How fast is Biogen Inc. growing?
BIIB's revenue grew at roughly -6.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Biogen Inc. have?
As of fiscal year 2025, BIIB carried roughly $6.29B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Biogen Inc.'s gross margin?
BIIB's gross margin was 75.7% in fiscal 2025 — gross profit of $7.49B on revenue of $9.89B.
What is Biogen Inc.'s market cap?
Biogen Inc. (BIIB) has a market capitalization of about $29.39B, based on the latest data in our nightly-refreshed cache.
When does Biogen Inc.'s fiscal year end?
BIIB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BIIB stock?
At today's market cap of $29.39B, Biogen Inc. is priced for free-cash-flow growth of about 3.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.05B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -11.6%/yr over the last five fiscal years and revenue -6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Biogen Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.